February 25, 2013 at 12:08 PM EST
VIVUS Obesity Drug Sales Only About 60% Of Expectations
DailyFinance.com : VIVUS Inc. (NASDAQ: VVUS) reported a quarterly loss of -$0.56 per share on Monday, but this was not an earnings story. VIVUS remains a developing story about its obesity drug Qsymia. Its revenue came to only $1.97 million, and that is shy of the ... Read more
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here